These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11367132)

  • 1. Salvage solitaire (or, HAART takes a holiday).
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):10-23. PubMed ID: 11367132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 6. The great salvage therapy drug juggle.
    Cadman J
    GMHC Treat Issues; 1998 Apr; 12(4):1-6. PubMed ID: 11365398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy.
    Gulick RM
    AIDS Clin Care; 1999 Sep; 11(9):71-3, 77-8. PubMed ID: 11366502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More trouble for adefovir.
    Gilden D
    GMHC Treat Issues; 1999 Apr; 13(4):3. PubMed ID: 11366975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapies get attention at conference.
    Rodriguez E
    Posit Living; 1999 Nov; 8(10):6, 45, 47. PubMed ID: 11367335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy: still more intuition than data.
    Gilden D
    GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
    J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.